5HT6対抗性/HDAC6阻害性を持つインテピルジン誘導体
Andreas Gkanas1, Maria Koutiva1, Theodora Katsila2
1Department of Chemistry, University of Patras, Rio Campus, Achaia, 26504, Greece.
Chemistry (Weinheim an der Bergstrasse, Germany)
|August 22, 2025
まとめ
研究者らは,5-HT6受容体とHDAC6酵素の両方を標的とした新しい二重作用薬を開発しました. この化合物は アルツハイマー病などの 認知機能の改善に 役立つ可能性を示しています
科学分野:
- 神経科学
- 薬剤化学
- 薬理学について
背景:
- アルツハイマー病 (AD) と他の認知症は,有効な治療法が限られているので,生活の質に大きな影響を与えます.
- 現在の薬は主に症状を治す一方 標的治療は臨床試験の失敗に直面しています
- マルチターゲティング・リガンドは 複雑な神経変性疾患に対する有望な戦略として 複数の生物学的メカニズムに対応します
研究 の 目的:
- 5-HT6受容体とHDAC6酵素の両方を標的にする新しい二重作用リガンドの設計と合成.
- 認知機能強化剤として これらの化合物の可能性を 探求する
- 神経変性疾患の治療法として
主な方法:
- アリルヒドロキサミ酸の薬剤ホルモンをインテピルジンと結合して設計・合成された二重の5-HT6 抗体/ HDAC6 阻害剤.
- インテピルディンのグラムスケール合成を開発した.
- 合成された誘導体の抑制効能と受容体の親和性を特徴づけた.
主要な成果:
- 成功して合成された新しい二重作用の5-HT6抗体/ HDAC6阻害剤.
- 誘導体RG- 283AGは,HDAC6に対する微小分子の効能 (IC50 = 0. 54 μM) と5- HT6受容体に対するナノ分子の親和性 (Ki = 0. 7 nM) を示した.
- RG-283AGは 血脳障壁を通過する能力を示した.
結論:
- RG- 283AGは,潜在的認知機能強化特性を有する最初の報告された二重作用の5- HT6 / HDAC6リガンドです.
- アルツハイマー病や他の認知症の治療法の開発に 有望な戦略を示しています
- RG- 283AGの治療的可能性に関するさらなる調査が必要である.
関連する概念動画
Antidepressant Drugs: MAOIs and Other Agents
344
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
344
Dipeptidyl Peptidase 4 Inhibitors
256
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
256
Sedatives and Hypnotics Drugs: Miscellaneous Agents
241
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
241
Antipsychotic Drugs: Typical and Atypical Agents
314
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
314
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
321
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
321
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
400
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
400


